Share Twitter LinkedIn Facebook Email Christopher Jakubowski, MD The Johns Hopkins discusses an abstract from The Journal of Clinical Oncology entitled Response to Crizotinib in ROS1 Fusion–Positive Intrahepatic Cholangiocarcinoma
Promising Phase 2 Results for Zanidatamab in HER2+ Biliary Tract Cancer: ASCO 2024 Update ASCO Annual Meeting 2 Mins Read
Ghassan Abou-Alfa, MD – HIMALAYA Phase III trial – Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi.m4v Liver 3 Mins Read